Bone News and Research

RSS

Revlimid receives approval in Switzerland for treatment of multiple myeloma

Celgene International Sarl has announced that it's oral cancer drug, Revlimid (lenalidomide) has been granted approval by the Swiss Agency for Therapeutic Products (Swissmedic) for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy.

5 Sep 2007

Study identifies osteopontin as a key player in the body's immune response to chronic stress

Osteopontin (OPN), a protein molecule involved in many different cellular processes, plays a significant role in immune deficiency and organ atrophy following chronic physiological stress, resulting in increased susceptibility to illness.

4 Sep 2007

Taking paracetamol slows down bone growth

In Medicine, paracetamol is used to soothe every kind of pain, from simple molar pain to pain produced by bone fractures.

4 Sep 2007

Mice stressed in simulated weightlessness show organ atrophy

A ground-based, experimental model used to simulate astronaut weightlessness in space has provided Rutgers scientists an opportunity to study the effects of stress on immune organs.

4 Sep 2007

FDA approves Acambis smallpox vaccine

Acambis plc (Acambis) has announced that the US Food and Drug Administration (FDA) has approved its ACAM2000 (Smallpox (Vaccinia) Vaccine, Live) vaccine for protection against smallpox.

4 Sep 2007

Symposium on children born with clubfoot

We often think that high-tech, surgical methods are the best approach when it comes to medical care. But for children born with clubfoot, there is growing, worldwide interest in a low-tech, non-surgical method of treatment that is more effective, less expensive and easier to provide than surgery.

3 Sep 2007

Greater use of spinal fusion has not lowered risk of repeat back surgery

Despite new implant technologies and surgical techniques leading to increased rates of spinal fusion surgery, the percentage of patients requiring further low-back surgery after spinal fusion has actually increased since the early 1990s, reports the Sept. 1 issue of the journal Spine, published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

3 Sep 2007

Does physical activity provide a molecular key to longevity?

Fitness and physical exercise are among the most neglected means to improve prognosis. They are the healthiest cardiovascular intervention. Even cardiologists focus on pharmacological treatment and evaluate classical risk factors without asking about daily exercise or objective measures of physical capacity. It is surprising considering the strong data that underscores the survival benefit of regular exercise training.

2 Sep 2007

Discovery of novel cause of iron overload in patients with thalassemia

According to the study, thalassemia patients overproduce a protein called GDF15, which suppresses the production of a liver protein, hepcidin, which in turn leads to an increase in the uptake of dietary iron in the gut.

30 Aug 2007

New insights into knee injuries and osteoarthritis in the knee

The sort of swelling that occurs when a joint is damaged by injury or degeneration is normally essential to the healing process, but when it comes to the knee, that inflammation can actually interfere with healing.

30 Aug 2007

New anti-cancer drug made from corn lillies kills brain tumor stem cells

A drug that shuts down a critical cell-signaling pathway in the most common and aggressive type of adult brain cancer successfully kills cancer stem cells thought to fuel tumor growth and help cancers evade drug and radiation therapy, a Johns Hopkins study shows.

30 Aug 2007

Genetics of imatinib resistance in acute lymphoblastic leukemia

In the September 15th issue of Genes & Development, Drs. Richard T. Williams, Willem den Besten, and Charles J. Sherr at Howard Hughes Medical Institute, St. Jude Children's Research Hospital in Memphis TN, lend new insights into how an aggressive form of acute lymphoblastic leukemia (ALL) develops, and how sensitivity to the targeted chemotherapeutic drug, imatinib, can be diminished through interactions between tumor cells and the host microenvironment.

30 Aug 2007

Researchers discover what makes lymphomas tick

University of Pennsylvania researchers and their colleagues at the Wistar Institute and University of Oxford have discovered the molecular process by which the PAX5 protein, necessary for lymphocyte development, promotes the growth of common lymphomas, thereby unveiling a potential new target in the fight against cancer.

30 Aug 2007

Biologic treatment for rheumatoid arthritis and the risk of cancer

The relationship between rheumatoid arthritis (RA), an autoimmune disease marked by chronic inflammation of the joints and tissue surrounding vital organs, and the incidence of cancer is complicated.

30 Aug 2007

Genial bone advancement trephine effective treatiment for sleep apnea

Sleep disorder and ear, nose and throat specialists at Thomas Jefferson University are examining an innovative procedure to treat obstructive sleep apnea syndrome.

29 Aug 2007

FDA grants orphan drug designation to TREANDA

Cephalon, Inc. announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for the company's investigational therapy, TREANDA (bendamustine HCl), for the treatment of chronic lymphocytic leukemia (CLL).

29 Aug 2007

St. Jude discovers factors that accelerate resistance to Gleevec targeted therapy in lymphoblastic leukemia

Results of a study by investigators at St. Jude Children's Research Hospital provide strong evidence for why the drug imatinib (Gleevec), which has revolutionized the treatment of chronic myelogenous leukemia (CML), is often unable to prevent relapse of a particularly aggressive form of acute lymphoblastic leukemia (ALL).

29 Aug 2007

New type of male sling procedure to improve the urinary control

Michael Yarborough, a 58-year-old business owner from Waxahachie, Texas, was fortunate. A routine check-up three years ago revealed prostate cancer, but a side effect of his successful surgery was "driving him nuts."

29 Aug 2007

Animal model for dengue research

A mosquito-borne disease often known as "break-bone fever" has found a new enemy in a unique type of mouse.

28 Aug 2007

Secret to bone's strength

Scientists and engineers are eager to understand the secret behind bone's lightweight toughness so they can mimic it in the design of new materials, but previous studies have revealed a number of different strength mechanisms at different scales of focus, rather than a single theory.

28 Aug 2007